Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Debt-to-Equity : -2.43 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Debt-to-Equity?

Parnell Pharmaceuticals Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2018 was $0.01 Mil. Parnell Pharmaceuticals Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2018 was $32.28 Mil. Parnell Pharmaceuticals Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2018 was $-13.28 Mil. Parnell Pharmaceuticals Holdings's debt to equity for the quarter that ended in Dec. 2018 was -2.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Debt-to-Equity or its related term are showing as below:

PARNF's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Parnell Pharmaceuticals Holdings Debt-to-Equity Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Debt-to-Equity Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.86

3.70

-2.84

-2.43

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Debt-to-Equity	Get a 7-Day Free Trial			0.12	0.86	3.70	-2.84	-2.43

Competitive Comparison of Parnell Pharmaceuticals Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Debt-to-Equity falls into.

Parnell Pharmaceuticals Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Parnell Pharmaceuticals Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.007	+	32.282)	/	-13.282
	=	-2.43

Parnell Pharmaceuticals Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.007	+	32.282)	/	-13.282
	=	-2.43

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Parnell Pharmaceuticals Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.